HHC Has Its Own Schedule I Code Now, and a Second Federal Deadline Lands in November

The DEA published a final rule assigning hexahydrocannabinol the drug code 7220 and listing it specifically in Schedule I. Before the rule, HHC was controlled under the general tetrahydrocannabinols code 7370. The agency described the amendment as technical and said it makes no substantive difference in HHC’s status.

Running alongside it is a statute that matters more for what is on shelves. Section 781 of the November 2025 appropriations law narrows the federal definition of hemp, and the exclusion covering cannabinoids that a cannabis plant cannot naturally produce takes effect November 12, 2026. HHC sits squarely in that category under the government’s own reading.

The hemp-derived intoxicant market grew on the argument that the 2018 Farm Bill’s hemp definition swept in anything made from a hemp molecule. Patients absorbed that argument as fact. A person buying an HHC vape at a gas station generally believes they are buying a legal product, and some believe they are buying a medical one.

Neither the pharmacology nor the law supported that confidence. What has changed in 2026 is that both the enforcement infrastructure and the statutory text are catching up, on two different clocks, and anyone advising patients should know which clock is which.

The rule, Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance, was published May 4, 2026 at 91 FR 23913, Federal Register document 2026-08595, under docket DEA-1632. It amends 21 CFR 1308.11(d) by adding paragraph (115) and assigns HHC the drug code 7220. It took effect on publication.

The title carries the government’s whole argument. HHC is described as a currently controlled substance, not a newly controlled one. The DEA’s position is that HHC met the definition of tetrahydrocannabinols under the Controlled Substances Act and has been controlled under the general code 7370, so the specific listing is administrative housekeeping. The agency stated that the rule makes no substantive difference in HHC’s status.

The practical function of a discrete code is enforcement and accounting. It lets the agency set aggregate production quotas and individual manufacturing and procurement quotas for registered handlers, and it lets tracking and prosecution reference HHC directly rather than through a category.

The DEA did not open the rule for public comment. It invoked 5 U.S.C. 553(b)(B), the exception that permits an agency to forgo notice and comment when the process would be unnecessary, and characterized the action as a minor or merely technical amendment with no substantive change to HHC’s controlled status. It also made the rule effective immediately, saying a delay could cause confusion about regulatory status.

That reasoning is internally consistent and also contestable. If HHC was controlled before, a code assignment is bookkeeping. If it was not, then the rule is the operative act and the procedural shortcut is doing real work. Hemp industry litigants have pressed the second reading, and this is the seam any future challenge runs along.

For a patient, the procedural question is secondary. The enforcement posture of the federal government toward HHC is not ambiguous regardless of how the rule was adopted.

The 2018 Farm Bill excluded hemp, meaning Cannabis sativa L. with no more than 0.3 percent delta-9 THC by dry weight, from the Controlled Substances Act, including the tetrahydrocannabinols in that material. The industry reading was that a molecule made from a hemp-derived starting material inherits the exemption.

The DEA reads the exemption as covering what the plant produces, not what a laboratory makes from it. The rule states the position directly: tetrahydrocannabinols produced through chemical conversion, even when hemp derived, are considered synthetically produced for purposes of the Controlled Substances Act.

The agency applied that reasoning to HHC earlier, in an April 3, 2024 letter from Terrence L. Boos, chief of the Drug and Chemical Evaluation Section, to the Louisiana Department of Health. That letter concluded that HHC does not occur naturally in the Cannabis sativa L. plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp. It also noted that the determination could change if scientific evidence establishing natural occurrence emerged.

Section 781 of Public Law 119-37, the appropriations act signed November 12, 2025, rewrote the federal hemp definition. It replaces the delta-9 threshold with a 0.3 percent total THC standard inclusive of THCA, adds a 0.4 milligram total THC per container cap on finished products, and excludes products containing cannabinoids that a Cannabis sativa L. plant cannot naturally produce, along with cannabinoids that the plant could produce but that were synthesized or manufactured outside it. The changes carried a one year delay to November 12, 2026.

On September 2, 2026, the president signed H.R. 6500, the Continuing Appropriations and Extensions Act, 2027. Section 2019 of that law postpones most of the Section 781 amendments to December 11, 2026. It does not postpone the exclusion for cannabinoids that cannot be naturally produced by the plant. That category stays on the original November 12, 2026 schedule.

Under the government’s own position that HHC cannot be obtained except synthetically, HHC falls in the category that was not delayed. A patient tracking this needs two dates, not one, and the earlier date is the one that reaches HHC.

Pharmacology is where the clinical objection sits, independent of any legal question. HHC is produced by hydrogenating THC, and hydrogenation creates a stereocenter. Commercial HHC is not one molecule but a mixture of epimers, and the two forms do not behave identically at the CB1 receptor.

Forensic data make the point concretely. A study in Drug Testing and Analysis examined 1,186 cannabis-type samples seized in Poland between 2022 and 2024 and found semisynthetic cannabinoids in 113 of them, with HHC the predominant compound. HHC appeared consistently as a mixture of two epimers, with the 9R form prevailing at a typical ratio between 2.0 and 2.8 to 1. In roughly 60 percent of cases the material had been applied to plant matter with low THC content, which the authors read as deliberate enrichment of otherwise weak material.

The same paper documents why testing does not rescue the situation. Gas chromatography can degrade acetate forms, ultraviolet detection struggles to separate compounds with similar spectra, and high resolution mass spectrometry cannot fully distinguish structural or stereoisomeric forms. A certificate of analysis on an HHC product is reporting a number whose underlying identity is genuinely hard to pin down.

Start without accusation. Most people using HHC were told it was legal hemp, and many arrived at it because licensed access was inconvenient, expensive, or unavailable in their state. Treating that as a compliance failure rather than an access problem ends the conversation.

The clinically useful questions are the ordinary ones. What is the product, how much, how often, by what route, and alongside which medications. HHC is a CB1 agonist, so the interaction, impairment, and cardiovascular considerations that apply to THC apply here, with the added uncertainty that the delivered dose is unverifiable.

Then the practical point. Whatever a patient concludes about federal enforcement risk, the product quality argument stands on its own. A licensed medical or adult-use supply chain has mandatory testing, defined cannabinoid content, child-resistant packaging, and a clinician who can see the whole medication list. The hemp intoxicant market has none of that, which is the reason to move, more than the drug code is.

This is a primary regulatory document rather than a scientific one, and it should be read as such. The Federal Register text states the agency’s legal position, the procedural authority it relied on, and the effective date. Those facts are not in dispute and do not require interpretation.

What the document cannot settle is whether a reviewing court agrees with the DEA’s construction of the hemp exemption. An agency’s stated reading of a statute is authoritative until it is not, and hemp litigants have challenged this construction. The enforcement reality and the final legal answer are separate things, and only the first is settled today.

The technical amendment framing does real work in this rule, and it deserves scrutiny. Waiving notice and comment on the ground that nothing substantive is changing presumes the conclusion that HHC was already controlled, which is precisely the question industry contests. A challenger would argue the agency used a procedural shortcut to settle a substantive dispute.

The DEA’s factual premise also carries a caveat the agency itself wrote down. The 2024 letter said the determination rests on HHC not occurring naturally in the plant and could change if evidence to the contrary emerged. Reporting that treats natural occurrence as conclusively resolved is overstating a position the agency stated conditionally.

This rule does not create a new prohibition, according to the agency, and it does not resolve the litigation over whether chemically converted cannabinoids fall inside the hemp exemption. It does not address delta-8 THC, THC-O, THCP, or any other converted cannabinoid, each of which has its own record.

It also says nothing about state law. States vary widely in how they treat HHC and other hemp intoxicants, and a substance controlled federally can still be regulated, banned, or tolerated differently at the state level. A patient asking what applies to them needs a state answer as well as a federal one.

The pattern here has repeated since 2019. A definitional gap opens, manufacturers move into it, products reach retail with no testing requirement, regulators respond slowly and inconsistently, and the eventual correction arrives after several years of unsupervised consumption. Delta-8 ran this course first. HHC ran it second.

What is different in 2026 is that Congress, rather than an agency, has rewritten the definition. Section 781 does not depend on how the DEA construes the word derived, because it names synthesized and manufactured cannabinoids in the statute. That is a more durable fix than an agency letter, and it is the reason the November date matters more to the market than the drug code does.

None of this surprises me. The claim that HHC was legal hemp rested on reading one sentence of the Farm Bill in isolation and ignoring the rest of the controlled substances framework. It grew because enforcement was slow, not because the legal theory was strong.

But the legal question is not what concerns me most. I have spent years looking at products patients bring in from smoke shops and hemp retailers, and the recurring feature is that nobody in the chain can tell me what is in the package. Not the ratio, not the isomer mix, not the residual solvents from the conversion step, not the actual milligrams per serving. When the forensic literature says the analytical instruments themselves struggle to separate these stereoisomers, the certificate of analysis on the box is not reassurance.

The people using these products are not reckless. They are usually trying to solve a real problem with the access they have. My argument to them is not that they broke a rule. It is that they are dosing something whose identity nobody has established, and that we built an entire field of cannabis medicine specifically to stop doing that.

HHC now has its own Schedule I drug code, and the DEA’s position is that this formalizes control that already existed rather than creating it. The more consequential date is November 12, 2026, when the statutory exclusion for cannabinoids a cannabis plant cannot naturally produce takes effect and is not covered by the delay Congress passed in September. Patients using HHC should have that exposure documented and should be offered a regulated alternative.

Hold two dates and one distinction. May 4, 2026 was an administrative listing. November 12, 2026 is a statutory exclusion that reaches synthesized cannabinoids and was not postponed. The distinction is between a rule that says HHC has been controlled and a law that says a product containing it is not hemp. Those are different mechanisms arriving at the same place.